Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Other Accumulated Expenses (2019 - 2025)

Historic Other Accumulated Expenses for Summit Therapeutics (SMMT) over the last 7 years, with Q3 2025 value amounting to $2.0 million.

  • Summit Therapeutics' Other Accumulated Expenses rose 9045.76% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year increase of 9045.76%. This contributed to the annual value of $1.8 million for FY2024, which is 15062.76% up from last year.
  • Summit Therapeutics' Other Accumulated Expenses amounted to $2.0 million in Q3 2025, which was up 9045.76% from $1.5 million recorded in Q2 2025.
  • Summit Therapeutics' 5-year Other Accumulated Expenses high stood at $2.0 million for Q3 2025, and its period low was $209000.0 during Q3 2022.
  • For the 5-year period, Summit Therapeutics' Other Accumulated Expenses averaged around $828473.7, with its median value being $717000.0 (2023).
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first surged by 19096.05% in 2021, then plummeted by 7970.87% in 2022.
  • Summit Therapeutics' Other Accumulated Expenses (Quarter) stood at $897000.0 in 2021, then fell by 26.2% to $662000.0 in 2022, then grew by 8.31% to $717000.0 in 2023, then surged by 150.63% to $1.8 million in 2024, then rose by 8.85% to $2.0 million in 2025.
  • Its Other Accumulated Expenses was $2.0 million in Q3 2025, compared to $1.5 million in Q2 2025 and $759000.0 in Q1 2025.